دورية أكاديمية
أعرض في EDS

Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy

التفاصيل البيبلوغرافية
العنوان: Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy
المؤلفون: Groessl EJ, Tally SR, Hillery N
المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 239-250 (2023)
بيانات النشر: Dove Medical Press, 2023.
سنة النشر: 2023
المجموعة: LCC:Medicine (General)
LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: copd, acute exacerbations, cost-effectiveness, humidified high flow therapy, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
الوصف: Erik J Groessl,1,2 Steven R Tally,1 Naomi Hillery1 1Health Services Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, CA, USA; 2VA San Diego Healthcare System, San Diego, CA, USACorrespondence: Erik J Groessl, University of California San Diego, Health Services Research Center, 9500 Gilman Drive, Mail Code 0994, San Diego, CA, 92037, USA, Tel +1 858 622 1771, Email egroessl@health.ucsd.eduPurpose: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality, and is associated with significant respiratory impairment, decreased quality of life, and high health care costs. Recent evidence indicates significant clinical benefit results from adding humidified high-flow therapy (HHFT) to standard long-term oxygen therapy (LTOT) as a home-based therapy in persons with severe COPD. The objective was to evaluate the cost-effectiveness of adding HHFT to standard treatment of COPD patients using LTOT with US healthcare cost estimates.Patients and Methods: A Markov state-transition model was developed using data from a prospective clinical trial of adding HHFT to standard therapy for persons with severe COPD using LTOT. The analysis was conducted from the US health care system perspective using a 5-year time horizon and 3% discount rate. QALYs and downstream healthcare costs were modeled. One-way and probabilistic sensitivity analyses were used to examine the impact of input parameters on the incremental net monetary benefit (NMB).Results: Incremental QALYs accrued were 0.058 (2.047 vs 1.989 QALYs for HHFT and standard therapy groups respectively). Incremental total costs were -$3939 ($47,516 vs $51,455 for HHFT and standard therapy groups respectively). Thus, HHFT was the dominant treatment in the analysis, resulting on both better health and lower total costs. Varying utility and cost inputs individually never resulted in NMB approaching 0. Probabilistic analyses indicate that HHFT is cost-effective in 84% of simulations.Conclusion: Our results indicate that the reductions in acute exacerbations of COPD (AECOPDs) that result from adding HHFT for persons with COPD on LTOT will produce both health benefit (QALYs) and cost savings. Cost savings occur because the HHFT device costs are more than offset by reductions in costly COPD exacerbations. Health care systems and payors can benefit from wider implementation of HHFT with existing treatments.Keywords: COPD, acute exacerbations, cost-effectiveness, humidified high flow therapy
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6981
Relation: https://www.dovepress.com/cost-effectiveness-of-humidified-high-flow-therapy-hhft-for-copd-patie-peer-reviewed-fulltext-article-CEOR; https://doaj.org/toc/1178-6981
URL الوصول: https://doaj.org/article/a82883e78c1d43d2b253093bbb203580
رقم الأكسشن: edsdoj.82883e78c1d43d2b253093bbb203580
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11786981